Beam Therapeutics filed suit alleging IP theft tied to its CRISPR base editing technology, naming a former scientist and two China-linked biotech entities. The company claims that Zi Jun “Emma” Wang accessed Beam’s electronic lab notebooks outside working hours and used confidential information to co-found YolTech Therapeutics, later leading to a VC-backed startup structure. Beam’s complaint also targets Serapha Bio, which the article notes has licensed the therapy associated with YolTech as part of a new startup venture backed by RA Capital and RTW. Both YolTech and Serapha are named as defendants. The legal action reflects heightened scrutiny inside the industry around cross-border gene-editing know-how, particularly as base editing and next-generation CRISPR approaches move toward broader commercialization timelines. If Beam’s allegations prove out, the case could impact program continuity, licensing terms, and how companies police access controls for sensitive platform IP while scaling research operations.